Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Physical Frailty Intervention for Older Adults With Hypertension and Physical Frailty (PFIM)

12 de noviembre de 2026 actualizado por: Dong Yuan

Development and Evaluation of Physical Frailty Intervention Module for Older Adults With Hypertension in Shandong Province, China

Physical frailty is a common health concern among older adults with hypertension and may contribute to reduced physical function, loss of independence, and poorer quality of life. This study aims to evaluate the effectiveness of a 12-week nurse-led Physical Frailty Intervention Module (PFIM) among community-dwelling older adults with hypertension and physical frailty in Shandong Province, China.

This nonrandomized controlled study will recruit 124 participants aged 60 years or older from three primary healthcare institutions. Two institutions will be assigned to the intervention group, which will receive the PFIM in addition to usual care, while one institution will serve as the control group and provide usual care only.

The PFIM is based on the Health Action Process Approach (HAPA) and combines simplified Baduanjin exercise, basic nutrition guidance, hypertension self-management education, and behavioral support. The intervention includes nurse-led group sessions, individualized home-based exercise, and follow-up support over 12 weeks.

Physical frailty will be the primary outcome. Physical performance, nutritional status, health literacy, perceived social support, depressive symptoms, and quality of life will be assessed as secondary outcomes at baseline and after 12 weeks.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

This study is the third phase of a multiphase research project involving the development, validation, and evaluation of a Physical Frailty Intervention Module (PFIM) for older adults with hypertension and physical frailty.

A pragmatic, two-arm, nonrandomized controlled quasi-experimental design will be used. The study will be conducted at three primary healthcare institutions in Yanzhou District, Jining, Shandong Province, China. Two institutions will be allocated to the intervention group and one to the control group to minimize contamination. The planned sample size is 124 participants, with 62 participants per group.

The 12-week PFIM is informed by the Health Action Process Approach (HAPA) and delivered by trained nurses. It comprises three stages:

Weeks 1-4 focus on motivation and participation preparation through weekly face-to-face group education sessions addressing physical frailty, hypertension, nutrition, exercise safety, and behavioral change.

Weeks 5-8 emphasize action planning and behavior initiation through weekly group sessions and home-based simplified Baduanjin practice two to three times weekly for 15-20 minutes per session.

Weeks 9-12 focus on behavior maintenance through continued home practice, progressing toward 20-30 minutes per session when appropriate, with group sessions in Weeks 9 and 12 and telephone or WeChat follow-up in Weeks 10 and 11.

Standing or seated simplified Baduanjin exercises will be assigned according to participants' physical performance and clinical safety assessments. The control group will receive usual hypertension care without the structured PFIM.

The primary outcome is physical frailty severity, measured using the FRAIL Scale. Secondary outcomes include physical performance (SPPB), nutritional status (MNA-SF), health literacy (HLS-SF12), perceived social support (PSSS), depressive symptoms (GDS-15), and quality of life (OPQOL-brief). Outcomes will be assessed at baseline and immediately after the 12-week intervention.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

124

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Shandong
      • Jining, Shandong, Porcelana, 272100
        • Caohe Town Health Center
        • Contacto:
      • Jining, Shandong, Porcelana, 272100
        • Jiuxianqiao Subdistrict Community Health Service Center
        • Contacto:
      • Jining, Shandong, Porcelana, 272100
        • Yandian Central Health Center
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

60 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Aged 60 years or older.
  • Physician-diagnosed hypertension or current use of physician-prescribed antihypertensive medication.
  • Physical frailty, defined as a FRAIL Scale score of 3 or higher.
  • Community-dwelling and residing within the catchment area of one of the participating primary healthcare institutions.
  • Adequate cognitive and communication abilities to understand study procedures, communicate in Mandarin or the local dialect, complete questionnaires with or without assistance, and provide written informed consent.
  • Medically stable and considered fit for light-to-moderate physical activity by the treating physician.

Exclusion Criteria:

  • Major acute illness requiring hospitalization within the preceding three months, such as acute myocardial infarction, acute stroke, or acute decompensated heart failure.
  • Current participation in another structured health promotion, rehabilitation, or exercise program.
  • Disabling stroke, active or advanced cancer, advanced heart failure, severe chronic obstructive pulmonary disease, or another serious medical condition that makes participation unsafe or substantially limits life expectancy.
  • Adjusted Montreal Cognitive Assessment (MoCA) score below the prespecified education-specific thresholds: <14 for illiterate participants, <15 for those with primary-school education, or <21 for those with junior-secondary education or above. One additional point is applied for fewer than 12 years of education, up to a maximum score of 30.
  • Major visual, hearing, speech, or other communication impairment that prevents meaningful participation.
  • Severe uncontrolled psychiatric disorder, major neurocognitive disorder, or end-stage disease that prevents comprehension, cooperation, or safe participation.
  • Any other condition considered medically unsuitable for participation by the treating physician.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: PFIM Intervention Group

Participants in this group will receive the 12-week nurse-led Physical Frailty Intervention Module (PFIM) in addition to usual primary healthcare for hypertension. The intervention includes simplified Baduanjin exercise, nutrition guidance, hypertension self-management education, individualized action planning, self-monitoring, and follow-up support.

The Physical Frailty Intervention Module (PFIM) is a 12-week nurse-led behavioral intervention based on the Health Action Process Approach (HAPA). During Weeks 1-4, participants attend weekly group education sessions on physical frailty, hypertension, nutrition, and exercise safety. During Weeks 5-8, participants attend weekly group sessions and begin home-based simplified Baduanjin practice 2-3 times per week for 15-20 minutes per session. During Weeks 9-12, home practice continues, progressing toward 20-30 minutes per session as tolerated, with group sessions in Weeks 9 and 12 and telephone or WeChat follow-up in Weeks 10 and 11. Standing or seated exercises are assigned according to physical performance and safety assessments. The intervention is provided in addition to usual hypertension care.

Sin intervención: Usual Care Control Group

Participants in the control group will receive usual primary healthcare for hypertension, including routine blood pressure monitoring, medication management, general lifestyle advice, and regular follow-up. No structured Physical Frailty Intervention Module (PFIM) will be provided during the 12-week study period.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Physical Frailty Severity Measured by the FRAIL Scale
Periodo de tiempo: Baseline (Week 0) and Week 12

Physical frailty will be assessed using the five-item FRAIL Scale, covering fatigue, resistance, ambulation, illnesses, and weight loss. Each item is scored 0 or 1, yielding a total score from 0 to 5. Higher scores indicate greater frailty severity. Change will be calculated as the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Physical Performance Measured by the Short Physical Performance Battery (SPPB)
Periodo de tiempo: Baseline (Week 0) and Week 12

Physical performance will be assessed using the Short Physical Performance Battery (SPPB), comprising balance, 4-meter gait speed, and repeated chair stands. Each component is scored from 0 to 4, yielding a total score from 0 to 12. Higher scores indicate better physical performance. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Nutritional Status Measured by the Mini Nutritional Assessment-Short Form (MNA-SF)
Periodo de tiempo: Baseline (Week 0) and Week 12

Nutritional status will be assessed using the six-item Mini Nutritional Assessment-Short Form (MNA-SF). Total scores range from 0 to 14, with higher scores indicating better nutritional status. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Health Literacy Measured by the Health Literacy Survey-Short Form 12 (HLS-SF12)
Periodo de tiempo: Baseline (Week 0) and Week 12

Health literacy will be measured using the 12-item Health Literacy Survey-Short Form (HLS-SF12), covering healthcare, disease prevention, and health promotion. Responses are converted to a standardized index ranging from 0 to 50. Higher scores indicate better health literacy. Change is the Week 12 index minus the baseline index.

Baseline (Week 0) and Week 12
Change in Perceived Social Support Measured by the Perceived Social Support Scale (PSSS)
Periodo de tiempo: Baseline (Week 0) and Week 12

Perceived social support will be assessed using the 12-item Perceived Social Support Scale (PSSS), covering support from family, friends, and significant others. Each item is rated from 1 to 7, giving a total score from 12 to 84. Higher scores indicate greater perceived social support. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Depressive Symptoms Measured by the 15-Item Geriatric Depression Scale (GDS-15)
Periodo de tiempo: Baseline (Week 0) and Week 12

Depressive symptoms will be assessed using the 15-item Geriatric Depression Scale (GDS-15). Each item is scored 0 or 1, giving a total score from 0 to 15. Higher scores indicate more severe depressive symptoms. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12
Change in Quality of Life Measured by the Brief Older People's Quality of Life Questionnaire (OPQOL-brief)
Periodo de tiempo: Baseline (Week 0) and Week 12

Quality of life will be assessed using the 13-item Brief Older People's Quality of Life Questionnaire (OPQOL-brief). Items are scored on a five-point scale and coded so that higher scores indicate better quality of life. Total scores range from 13 to 65. Change is the Week 12 score minus the baseline score.

Baseline (Week 0) and Week 12

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

20 de noviembre de 2026

Finalización primaria (Estimado)

31 de marzo de 2027

Finalización del estudio (Estimado)

31 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

12 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • USM/JEPeM/KK/26040291

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant-level data will not be shared outside the study team due to participant privacy and confidentiality considerations.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .